Vraylar

Active Ingredient(s): Cariprazine
FDA Approved: * September 17, 2015
Pharm Company: * FOREST LABS LLC
Category: Antipsychotic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Vraylar Overview

Cariprazine, sold under the brand names Vraylar in the United States and Reagila in Europe, is an atypical antipsychotic which is used in the treatment of schizophrenia and bipolar mania.[1] It acts primarily as a D3 receptor and D2 receptor partial agonist, with high selectivity for the D3 receptor.[2] Positive Phase III study results were published for schizophrenia and mania in early 2012, and for bipolar disorder I depression from a Phase II trial in 2015.&...

Read more Vraylar Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cariprazine

Recent Vraylar Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cariprazine
  • Capsule: 1.5mg, 3mg, 4.5mg, 6mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vraylar: (5 results)

Sorted by National Drug Code
  • 61874-115 Vraylar 1.5 mg Oral Capsule, Gelatin Coated by Actavis Pharma, Inc.
  • 61874-130 Vraylar 3 mg Oral Capsule, Gelatin Coated by Actavis Pharma, Inc.
  • 61874-145 Vraylar 4.5 mg Oral Capsule, Gelatin Coated by Actavis Pharma, Inc.
  • 61874-160 Vraylar 6 mg Oral Capsule, Gelatin Coated by Actavis Pharma, Inc.
  • 61874-170 Vraylar Oral Kit by Actavis Pharma, Inc.

Other drugs which contain Cariprazine or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA